Tu187 - Development of NULISAseq™ Inflammation Panel 250 for Comprehensive Immune Profiling

ishara Ariyapala – Alamar Biosciences; Joanne Beer – Alamar Biosciences; lei Fang – Alamar Biosciences; Wei Feng – Alamar Biosciences; Qinyu Hao – Alamar Biosciences; sean Kim – Alamar Biosciences; Dwight Kuo – Alamar Biosciences; Anna Lee – Alamar Biosciences; Yuling Luo – Alamar Biosciences; Vasudha Murlidhar – Alamar Biosciences; helena Sun – Alamar Biosciences; Ming Yu – Alamar Biosciences; Bingqing Zhang – Alamar Biosciences

Abstract Text: Comprehensive profiling of cytokines and chemokines in blood can provide deeper insights into the mechanisms underlying this highly complex and heterogeneous group of diseases. However, many of these proteins are present at very low concentrations in plasma, below the limit of detection of current immunoassays. We recently developed an automated multiplex immunoassay technology, NULISA™, capable of attomolar-level sensitivity and high levels of multiplexing, and we demonstrated the performance characteristics of a 200-plex assay and its correlation with existing platforms1. Here we report the development of an expanded inflammation-focused panel called NULISAseq™ Inflammation Panel 250 targeting 200 cytokines/chemokines and their receptors and 50 other important inflammation and immune response-related proteins. The assay demonstrated high sensitivity, detecting 96.4% of the targets in at least 50% of plasma samples, and high precision, with median intra-plate CV of 8% and inter-plate CV of 11%. It also demonstrated the ability to quantify proteins of a wide dynamic range without diluting samples. Comprehensive testing for target specificity demonstrated that 93% of the assays in the panel had < 1% cross reactivity to nonspecific targets. In summary, with ultrahigh sensitivity and the most comprehensive coverage of inflammatory cytokines/chemokines, the Inflammation Panel 250 assay provides a powerful discovery tool for inflammation and immunology research at the systems level, which may lead to new diagnostic biomarkers and therapeutic targets.
1. Feng, W. et al. NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing. Nat Commun 14, 7238 (2023).